Aortyx develops bioresorbable endovascular devices that mimic the biomechanical environment of the aorta to promote tissue regeneration in patients with aortic diseases. Their technology facilitates cell migration and proliferation, addressing the limitations of traditional vascular treatments.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for aortic diseases often fall short due to their inability to facilitate natural tissue regeneration, leading to complications and limited long-term effectiveness. Traditional endovascular devices do not always promote sufficient cell migration and proliferation within the damaged aortic tissue.
Solution
Aortyx is developing a novel bioresorbable endovascular device designed to mimic the aorta's natural biomechanical environment, fostering tissue regeneration in patients with aortic diseases. The device's unique design provides a suitable environment for cell migration and proliferation, addressing the limitations of existing vascular treatments. By using a bioresorbable platform, the device minimizes discrepancies with the natural dynamics of the aorta, promoting better integration and long-term healing. The technology aims to provide a more effective and regenerative approach to treating aortic conditions.
Target Audience
The primary target audience includes vascular surgeons, interventional cardiologists, and hospitals specializing in the treatment of aortic diseases.
Features
- Bioresorbable material that degrades over time, leaving only regenerated tissue.
- Viscoelastic properties that mimic the natural mechanical behavior of the aorta.
- Regenerative design that promotes cell migration and proliferation.
- Potential for use as a drug delivery platform for targeted therapy.